Skip to main content

Table 2 The correlations between the ALI (and its components) and the clinicopathological factors

From: The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study

  ALI BMI (kg/m2) Albumin (g/dl) NLR
Median (range) p-value Median (range) p-value Median (range) p-value Median (range) p-value
Age
 < 65 34.17 (4.68–174.81)   21.73 (15.48–29.91)   4.0 (2.7–4.9)   2.66 (0.71–12.57)  
 ≥ 65 38.52 (4.61–175.07) 0.367 21.50 (15.30–33.76) 0.683 3.8 (2.5–4.8) 0.023 2.18 (0.58–13.56) 0.112
Gender
 Male 38.42 (4.61–174.81)   21.80 (15.32–29.91)   3.9 (2.5–4.7)   2.44 (0.71–13.56)  
 Female 36.81 (7.41–175.07) 0.341 20.88 (15.30–33.76) 0.246 3.9 (2.9–4.9) 0.714 2.41 (0.58–8.85) 0.459
Location of primary tumor
 Right side 41.44 (4.61–175.07)   22.05 (15.32–33.76)   3.9 (2.7–4.8)   1.95 (0.58–13.56)  
 Left side 33.70 (7.41–109.73) 0.137 21.39 (15.30–29.91) 0.628 3.95 (2.5–4.9) 0.617 2.53 (0.94–8.85) 0.069
Histological type
 Well, Moderately 36.81 (4.61–175.07)   21.50 (15.30–33.76)   3.9 (2.5–4.9)   2.48 (0.58–13.56)  
 Poorly, Mucinous 39.39 (12.96–101.80) 0.442 21.79 (16.98–27.34) 0.962 3.9 (3.2–4.6) 0.786 2.03 (1.05–4.95) 0.375
RAS status
 Wild type 40.35 (4.61–109.73)   21.20 (15.30–33.76)   4.1 (2.5–4.8)   2.08 (0.94–13.56)  
 Mutant type 37.29 (4.68–175.07) 0.203 21.80 (16.00–29.91) 0.652 4.0 (2.7–4.9) 0.829 2.66 (0.58–12.57) 0.075
Detection of unresectable tumor
 Synchronous 28.98 (4.61–175.07)   21.49 (16.00–33.76)   3.85 (2.5–4.8)   2.69 (0.58–13.56)  
 Metachronous 40.43 (9.31–109.73) 0.016 22.02 (15.30–29.29) 0.680 4.0 (3.1–4.9) 0.020 2.08 (0.97–6.33) 0.028
The number of organs affected by metastasis
 One organ 38.21 (7.41–175.07)   21.30 (15.30–29.91)   3.9 (2.5–4.9)   2.41 (0.58–7.77)  
 Multiple organs 36.13 (4.61–174.81) 0.968 21.80 (16.89–33.76) 0.535 3.9 (2.7–4.8) 0.718 2.48 (0.71–13.56) 0.930
Peritoneal dissemination
 Negative 35.42 (7.41–175.07)   21.60 (15.30–33.76)   3.9 (2.5–4.9)   2.52 (0.58–8.85)  
 Positive 39.39 (4.61–98.33) 0.365 21.86 (16.98–25.65) 0.339 4.0 (2.7–4.7) 0.190 2.04 (0.94–13.56) 0.282
Molecular targeted therapy
 Without 35.15 (11.17–174.81)   22.44 (16.12–33.76)   3.85 (2.5–4.8)   2.42 (0.71–6.07)  
 With 38.42 (4.61–175.07) 0.977 21.00 (15.30–29.91) 0.105 4.0 (2.7–4.9) 0.281 2.41 (0.58–13.56) 0.986
  1. ALI Advanced lung cancer inflammation index, BMI Body mass index, NLR Neutrophil to lymphocyte ratio